EQL Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:7JK Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
13 Nov 24	Sell€142,842	FÅRö Capital Ab	Company	26,000	€5.49
03 Oct 24	Buy€24,701	Martin Kristofferson	Individual	5,000	€4.94
24 May 24	Buy€219,453	Axel Schorling	Individual	53,903	€4.07
24 May 24	Buy€219,453	Axel Schorling	Individual	53,903	€4.07

Insider Trading Volume

Insider Buying: 7JK insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 7JK?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	623,988	2.15%
Institutions	2,450,149	8.43%
VC/PE Firms	8,101,348	27.9%
Private Companies	8,718,500	30%
General Public	9,169,625	31.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 14 shareholders own 68.45% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
30%	Cadila Pharmaceuticals Limited	8,718,500	€59.2m	0%	no data
27.9%	FÅRö Capital Ab	8,101,348	€55.0m	-0.32%	98.66%
4.34%	SEB Investment Management AB	1,261,255	€8.6m	0.23%	0.02%
1.51%	Carnegie Fonder AB	440,251	€3.0m	0%	0.03%
1.07%	Axel Schorling	311,016	€2.1m	0%	no data
1.06%	Cliens Kapitalförvaltning AB	306,928	€2.1m	0%	0.07%
0.88%	Alexander Brising	256,543	€1.7m	0%	no data
0.86%	Schroder Investment Management Limited	250,000	€1.7m	0%	no data
0.66%	Amundi Asset Management SAS	191,715	€1.3m	-14.9%	no data
0.07%	Martin Kristofferson	20,200	€137.1k	32.9%	no data
0.047%	Anna Jonsson	13,729	€93.2k	0%	no data
0.034%	Anders Mansson	10,000	€67.9k	0%	no data
0.034%	Per Svangren	10,000	€67.9k	0%	no data
0.0086%	Linda Neckmar	2,500	€17.0k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 01:39
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EQL Pharma AB (publ) is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Erik Hultgård	Carnegie Commissioned Research